LIGAND PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| Three months ended · Nine months ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| 2024 | 2023 | 2024 | 2023 | |
| Revenues and other income: | ||||
| Revenue from intangible royalty assets | $26,552 | $23,863 | $67,512 | $61,447 |
| Income from financial royalty assets | 5,157 | 25 | 6,454 | 1,026 |
| Royalties | 31,709 | 23,888 | 73,966 | 62,473 |
| Captisol | 6,255 | 8,608 | 22,967 | 24,450 |
| Contract revenue and other income | 13,848 | 372 | 27,388 | 16,290 |
| Total revenues and other income | 51,812 | 32,868 | 124,321 | 103,213 |
| Operating costs and expenses: | ||||
| Cost of Captisol | 2,449 | 3,485 | 8,237 | 8,871 |
| Amortization of intangibles | 8,258 | 8,238 | 24,701 | 25,316 |
| Research and development | 5,675 | 5,532 | 17,000 | 19,049 |
| General and administrative | 24,475 | 14,656 | 53,049 | 36,798 |
| Financial royalty assets impairment | — | — | 26,491 | — |
| Fair value adjustments to partner program derivatives | 7,812 | — | 7,812 | — |
| Total operating costs and expenses | 48,669 | 31,911 | 137,290 | 90,034 |
| Gain on sale of Pelican | — | (2,121) | — | (2,121) |
| Operating income (loss) from continuing operations | 3,143 | 3,078 | (12,969) | 15,300 |
| Non-operating income and expenses: | ||||
| Gain (loss) from short-term investments | 2,407 | (13,184) | 98,923 | 30,340 |
| Interest income | 1,347 | 2,263 | 6,124 | 6,018 |
| Interest expense | (741) | (1) | (2,154) | (525) |
| Other non-operating expense, net | (12,495) | (4,300) | (48,206) | (4,570) |
| Total non-operating (expenses) income, net | (9,482) | (15,222) | 54,687 | 31,263 |
| (Loss) income before income taxes from continuing operations | (6,339) | (12,144) | 41,718 | 46,563 |
| Income tax benefit (expense) | (833) | 1,871 | (14,662) | (10,932) |
| Net (loss) income from continuing operations | (7,172) | (10,273) | 27,056 | 35,631 |
| Net loss from discontinued operations | — | — | — | (1,665) |
| Net (loss) income | $(7,172) | $(10,273) | $27,056 | $33,966 |
| Basic net (loss) income from continuing operations per share | $(0.39) | $(0.59) | $1.50 | $2.07 |
| Basic net loss from discontinued operations per share | $— | $— | $— | $(0.10) |
| Basic net (loss) income per share | $(0.39) | $(0.59) | $1.50 | $1.97 |
| Shares used in basic per share calculation | 18,419 | 17,380 | 18,061 | 17,241 |
| Diluted net (loss) income from continuing operations per share | $(0.39) | $(0.59) | $1.46 | $2.00 |
| Diluted net loss from discontinued operations per share | $— | $— | — | $(0.09) |
| Diluted net (loss) income per share | $(0.39) | $(0.59) | 1.46 | $1.91 |
| Shares used in diluted per share calculation | 18,419 | 17,380 | 18,574 | 17,784 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.